Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
Ella Day | June 13, 2025 | News story | Medical Communications, Research and Development | European Alliance of Associations for Rheumatology, Rheumatology, bristol myers squibb, clinical trial, psoriatic arthritis
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly improved symptoms in adults with active psoriatic arthritis (PsA) compared to placebo. Findings were shared at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, taking place 11 to 14 June.
In the 16-week study, 54.2% of patients receiving Sotyktu achieved a 20% improvement in signs and symptoms of PsA, compared to 34.1% in the placebo group. Improvements were also seen in skin symptoms, joint pain, physical function and quality of life, with positive results across secondary endpoints including Psoriasis Area and Severity Index 75 and Assessment Questionnaire-Disability Index responses.
“The results from this phase 3 study highlight the potential of Sotyktu as a new way of treating this debilitating disease,” said Philip Mease, director of rheumatology research at Providence Swedish Medical Center, Sweden.
Additional data from the ongoing POETYK PsA-2 trial showed that patients continuing or switching to Sotyktu maintained or improved clinical outcomes through week 52. Across both studies, the safety profile remained consistent with previous trials, with no new safety concerns identified.
PsA is a chronic, inflammatory arthritis that often occurs in people with psoriasis. It causes joint pain, swelling and stiffness.
Sotyktu is the first oral, selective TYK2 inhibitor under investigation for PsA and is already approved for moderate-to-severe plaque psoriasis in several countries. BMS plans to engage with regulators about the potential approval of Sotyktu for PsA.
Ella Day
13/6/25
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
